low - Rare disease treatments for life-threatening pediatric conditions exhibit minimal demand elasticity regardless of economic conditions. Patients require therapy irrespective of GDP growth, and payers cover orphan drugs given lack of alternatives and severe disease burden. The ultra-rare patient population (~1,000 globally per indication) means market size is biologically constrained rather than economically driven.

Rising rates create moderate valuation pressure on pre-profitable biotech stocks as investors discount future cash flows more heavily and rotate toward current income. However, Mirum's strong balance sheet (3.31x current ratio, minimal debt at 1.09 D/E) and approaching profitability reduce financing risk. Higher rates may slow M&A activity in the sector, potentially delaying exit opportunities for investors. The company's commercial-stage status with established revenue partially insulates it from the severe multiple compression affecting early-stage biotechs.

growth - The stock attracts biotech growth investors focused on commercial-stage rare disease companies approaching profitability inflection. The 96% one-year return and 80%+ revenue growth appeal to momentum investors, while the orphan drug exclusivity and high gross margins attract fundamental growth managers. Institutional ownership likely concentrated among healthcare-focused funds (Perceptive Advisors, RTW Investments, RA Capital) rather than broad index investors. The pre-profitable status and high valuation multiples (11.3x P/S) deter value investors, while lack of dividends excludes income-focused strategies.